ADA and rheumatoid arthritis: Infliximab, a chimeric mAb that is administered intravenously, is associated with the formation of ADA in up to 50% of patients with rheumatoid arthritis, while even the humanised mAb adalimumab, which is administered subcutaneously, induces ADA in a significant proportions of these patients (12–37%) [46].